Dicerna Pharmaceuticals
Biopharmaceutical company that developed RNA interference (RNAi) therapeutics using its proprietary GalXC platform. Acquired by Novo Nordisk in 2021.
Location
Lexington, Massachusetts, USA
Founded
2006
Categories
biotech, rnai, therapeutics, genetic-medicine, acquired